ES2393927T5 - Composiciones tópicas - Google Patents

Composiciones tópicas Download PDF

Info

Publication number
ES2393927T5
ES2393927T5 ES06728329.1T ES06728329T ES2393927T5 ES 2393927 T5 ES2393927 T5 ES 2393927T5 ES 06728329 T ES06728329 T ES 06728329T ES 2393927 T5 ES2393927 T5 ES 2393927T5
Authority
ES
Spain
Prior art keywords
topical compositions
nacl
glycerol
benzalkonium chloride
myoinositol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06728329.1T
Other languages
English (en)
Other versions
ES2393927T3 (es
Inventor
Shabtay Dikstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resdevco Research and Development Co Ltd
Original Assignee
Resdevco Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36952425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2393927(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Resdevco Research and Development Co Ltd filed Critical Resdevco Research and Development Co Ltd
Publication of ES2393927T3 publication Critical patent/ES2393927T3/es
Application granted granted Critical
Publication of ES2393927T5 publication Critical patent/ES2393927T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

imagen1
imagen2
imagen3
imagen4
imagen5
Nºpaciente
de Satisfacción personal
Antes
Un mes
D
I D I
1
0 0 2
1
2
0 0 2 1
3
0 0 2 1
4
0 0 2 1
5
0 0 2 1
media
0 0 2 1
imagen6
Esencialmente se obtuvieron los mismos resultados usando mioinositol en lugar de xilitol. 5 Estudios en animales
a. Se trataron 3 conejos durante 3 meses dos veces al día con gotas oculares, ajustando el pH a 7,0. La sección transversal media de las células corneales epiteliales y el porcentaje de células dañadas se evaluaron mediante microscopía electrónica.
10
Tratamiento Sección transversal en 2 % de células dañadas
Ninguno
590 16 0,9 % de NaCl
542 28 0,01 % de cloruro de benzalconio + 0,9 % de NaCl
538 29 0,01 % de cloruro de benzalconio + 2,5 % de Glicerol
699 14 0,01 % de bromuro de cetrimonio + 0,9 % de NaCl
591 27 0,01 % de bromuro de cetrimonio + 2,5 % de Glicerol
625 19 0,1 % de Na2 EDTA + 0,9 % de NaCl
531 15 0,1 % de Na2 EDTA + 2,5 % de Glicerol
616 17 0,025 % de Polisorbato 80 + 0,9 % de NaCl
440 25 0,025 % de Polisorbato 80 + 2,5 % de Glicerol
600 18 2,5 % de Glicerol
605 17 0,01 % de cloruro de benzalconio + 4,5 % de Xilitol
554 19 0,01 % de cloruro de benzalconio + 5,4 % de Mioinositol
584 19 0,01 % de cloruro de benzalconio + 5,4 % de Manitol
570 21 El estudio anterior no pertenece a la invención.
b. Prevención de la sequedad cutánea (irritación) causada por laurilsulfato sódico al 2 % (Método:
7
imagen7

Claims (1)

  1. imagen1
ES06728329.1T 2005-05-16 2006-05-07 Composiciones tópicas Active ES2393927T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL16860305 2005-05-16
IL168603A IL168603A (en) 2005-05-16 2005-05-16 Pharmaceutical or cosmetic composition for the prevention and treatment of irritation of mucous cells or skin cells
PCT/IL2006/000537 WO2006123324A1 (en) 2005-05-16 2006-05-07 Topical compositions

Publications (2)

Publication Number Publication Date
ES2393927T3 ES2393927T3 (es) 2013-01-02
ES2393927T5 true ES2393927T5 (es) 2015-12-21

Family

ID=36952425

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12159243T Active ES2433271T3 (es) 2005-05-16 2006-05-07 Composiciones tópicas para la prevención y tratamiento de la irritación de las células de la mucosa
ES06728329.1T Active ES2393927T5 (es) 2005-05-16 2006-05-07 Composiciones tópicas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES12159243T Active ES2433271T3 (es) 2005-05-16 2006-05-07 Composiciones tópicas para la prevención y tratamiento de la irritación de las células de la mucosa

Country Status (8)

Country Link
US (2) US20080207771A1 (es)
EP (2) EP2465493B1 (es)
DK (2) DK2465493T3 (es)
ES (2) ES2433271T3 (es)
IL (1) IL168603A (es)
PL (2) PL2465493T3 (es)
PT (2) PT1888024E (es)
WO (1) WO2006123324A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183076B2 (en) 2005-05-16 2019-01-22 Resdevco Research And Development Co. L Topical compositions for treatment of irritation of mucous membranes
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
JP2011503113A (ja) 2007-11-13 2011-01-27 メリテイジ ファーマ，インク． 胃腸炎の治療用組成物
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
EP2363126A1 (en) * 2010-03-04 2011-09-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition comprising as active ingredient L-carnitine in combination with hydroxykynurenine-O-beta-DL-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation
EP2667853A4 (en) 2011-01-25 2014-08-20 Procter & Gamble LIPOSOME AND BODY HYGIENE COMPOSITION CONTAINING SAME
IL212725A (en) 2011-05-05 2016-06-30 Resdevco Res And Dev Co Glycerol Preparation for Non-surgical Conjunctivochalysis
US9511144B2 (en) 2013-03-14 2016-12-06 The Proctor & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives
CA2937213A1 (en) * 2014-01-28 2015-08-06 Resdevco Research And Development Co. Ltd. Composition comprising xylitol and cholecalciferol for topical treatment of skin and mucous membranes
ITUB20153104A1 (it) * 2015-08-13 2017-02-13 Sooft Italia S P A Contrada Molino 17 68333 Montegiorgio Fm Composizione ed uso di collirio a base di inositolo per migliorare l'accomodazione visiva dei pazienti
MX2019010471A (es) * 2017-03-05 2020-02-12 Resdevco Res And Development Co Ltd Gotas oculares para el tratamiento de la irritacion no causada por infeccion.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80298A (en) † 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
JPS63270625A (ja) * 1987-04-30 1988-11-08 Santen Pharmaceut Co Ltd 抗アレルギ−点眼剤
JPH0278619A (ja) * 1988-09-12 1990-03-19 Santen Pharmaceut Co Ltd 安定なピレノキシン点眼液
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
US5089255A (en) * 1989-06-26 1992-02-18 Colgate-Palmolive Company Dental remineralization
DE4229494A1 (de) * 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
DE4312656C2 (de) * 1993-04-19 1996-01-25 Beiersdorf Ag Kühlend wirkende kosmetische oder dermatologische Zusammensetzungen
GB9313329D0 (en) * 1993-06-28 1993-08-11 Scherer Ltd R P Softgel capsule shell compositions
TW274516B (es) * 1993-11-12 1996-04-21 Ciba Geigy Ag
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SK284919B6 (sk) * 1997-03-20 2006-02-02 Schering Corporation Spôsob výroby práškových aglomerátov a dávková forma s ich obsahom
EP0909558A3 (en) * 1997-08-29 1999-10-27 Santen Pharmaceutical Co., Ltd. Chroman derivative containing ophthalmic solution
FI974385A0 (fi) † 1997-12-01 1997-12-01 Xyrofin Oy Anvaendning av xylitol foer bekaempning av jaestinfektion och xylitolpreparat foer denna anvaendning
US6238648B1 (en) † 1999-03-25 2001-05-29 The Procter & Gamble Company Anti-caries oral care compositions and their methods of use
GB9928055D0 (en) † 1999-11-26 2000-01-26 Alcan Int Ltd Oral cleansing product
US6361806B1 (en) * 2000-02-23 2002-03-26 Michael P. Allen Composition for and method of topical administration to effect changes in subcutaneous adipose tissue
US6716819B2 (en) * 2000-05-19 2004-04-06 University Of Iowa Research Foundation Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections
AR035509A1 (es) * 2000-12-21 2004-06-02 Alcon Inc Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento
JP3782779B2 (ja) 2000-12-28 2006-06-07 株式会社資生堂 皮膚外用剤
JP4229422B2 (ja) 2001-07-04 2009-02-25 河野製紙株式会社 繊維ウェブ製品
ES2186569B1 (es) † 2001-09-28 2004-09-16 Lacer, S.A. Composiciones para el alivio de la xerostomia y el tratamiento de los trastornos asociados con la misma.
EP1458327B1 (en) * 2001-12-18 2006-12-06 Kanca, John, III Device for dental applications
US6890961B2 (en) † 2002-02-01 2005-05-10 Micelle Products, Inc. Clear micellized formulations of β-carotene and method of treating leukoplakia
US6492379B1 (en) * 2002-02-21 2002-12-10 Super Gen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
AU2002325220A1 (en) * 2002-05-24 2003-12-12 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Drop-forming ophthalmic gel preparation comprising diclofenamide and timolol
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
JP3797431B2 (ja) † 2003-09-08 2006-07-19 ライオン株式会社 口腔用組成物及びその製造方法

Also Published As

Publication number Publication date
US10660961B2 (en) 2020-05-26
DK1888024T4 (en) 2015-10-26
WO2006123324A1 (en) 2006-11-23
EP1888024B2 (en) 2015-07-15
ES2393927T3 (es) 2013-01-02
PT2465493E (pt) 2013-11-11
US20080207771A1 (en) 2008-08-28
PL2465493T3 (pl) 2013-12-31
EP1888024A1 (en) 2008-02-20
EP1888024B1 (en) 2012-08-29
EP2465493B1 (en) 2013-08-07
EP2465493A1 (en) 2012-06-20
ES2433271T3 (es) 2013-12-10
PL1888024T3 (pl) 2013-02-28
US20170354735A1 (en) 2017-12-14
IL168603A (en) 2011-05-31
PT1888024E (pt) 2012-12-04
DK2465493T3 (da) 2013-10-28
DK1888024T3 (da) 2012-11-26

Similar Documents

Publication Publication Date Title
ES2393927T5 (es) Composiciones tópicas
US7875271B2 (en) Ophthalmic composition comprising xanthan gum and glucose
TWI670057B (zh) 治療乾眼用滴眼劑
AR052252A1 (es) Formulaciones topicas de nepafenac
RU2013141845A (ru) Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа
Andrés-Guerrero et al. Targeting Schlemm’s canal in the medical therapy of glaucoma: current and future considerations
DE60219314D1 (de) Halogenhaltige zusammensetzung, verfahren zu deren herstellung und deren verwendung
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
HK1110207A1 (en) Ophthalmic compositions and methods of using the same
AR033151A1 (es) Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
JP4987078B2 (ja) 眼科用組成物
WO2002047673A3 (en) Methods and compositions to treat conditions associated with neovascularization
ES2772724T3 (es) Composición farmacéutica para la prevención y el tratamiento de enfermedades del ojo seco, que contiene imatinib como principio activo
KR101301839B1 (ko) 잔탄 검 및 아미노산을 함유하는 안과용 조성물
JP5632589B2 (ja) シリコーンハイドロゲルコンタクトレンズ用点眼剤
US10456374B2 (en) Pyrrolidone carboxylic acid (PCA) for ophthalmic use
JP2012006962A (ja) 眼科用組成物
JP2006052160A (ja) ドライアイ治療用眼科組成物
WO2016009982A1 (ja) 角結膜障害治療剤
US20180221417A1 (en) Treatment of dry eye using amnion released factors
RU2019110285A (ru) Стоматологическая пленка для лечения и профилактики альвеолита
RU2019110523A (ru) Стоматологическая пленка для лечения и профилактики альвеолита с фитопелоидной композицией
JP2005200411A (ja) 涙液層安定化剤
TH1195B (th) การพัฒนาประสิทธิภาพของตำรับยารักษาโรคพืช